Skip to main content

Table 1 Descriptive characteristics of the first breast cancer among 1-year survivors of a first primary breast cancer in 12 SEER registries, 1992–2016

From: Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992–2016

   Calendar period of first breast cancer diagnosis
  Overall 1992–1997 1998–2003 2004–2009 2010–2015
Characteristics of the first breast cancer N = 419,818 N = 89,052 N = 107,103 N = 107,828 N = 115,835
Overall, % 100.0 21.2 25.5 25.7 27.6
Year of diagnosis, mean years (SD) 2004.0 (6.8) 1994.6 (1.7) 2000.5 (1.7) 2006.5 (1.7) 2012.5 (1.7)
Age at diagnosis, years, %
 < 40 5.9 6.7 6.1 5.8 5.3
 40 to < 50 20.4 20.7 20.8 21.4 18.8
 50 to < 60 26.1 23.0 26.7 27.5 26.6
 60 to < 70 24.3 23.4 21.9 23.6 27.9
 ≥ 70 23.3 26.2 24.6 21.7 21.4
Age at diagnosis, mean years (SD) 58.8 (12.7) 59.2 (13.1) 58.8 (12.9) 58.4 (12.6) 59.0 (12.2)
Stage at diagnosis, %
 I 50.7 50.9 50.9 50.2 50.7
 II 36.0 33.8 35.4 36.7 37.7
 III 13.3 15.4 13.7 13.1 11.6
Histology, %
 Ductal 75.4 73.4 72.3 76.3 79.1
 Lobular 8.3 7.7 8.1 8.1 9.3
 Mixed 7.1 5.7 9.1 7.8 5.6
 Other 9.2 13.3 10.5 7.8 6.1
ER status, %
 Positive 73.1 62.0 68.6 76.4 82.8
 Negative 18.6 20.2 18.6 19.8 16.0
 Borderline/unknown 8.3 17.7 12.8 3.7 1.2
Initial treatment receipt, %
 Surgerya
  None 2.0 1.2 1.7 3.1
  BCS/unilateral mastectomy 87.9 91.3 89.5 83.4
  Contralateral prophylactic mastectomy 7.3 2.9 6.8 11.8
  Unknown 2.8 4.6 2.0 1.7
 Radiation therapy
  Yes 54.2 45.0 55.3 56.8 58.0
  No/unknown 45.8 55.1 44.7 43.2 42.1
 Chemotherapy
  Yes 40.5 31.3 41.9 45.0 42.0
  No/unknown 59.5 68.8 58.1 55.0 58.0
 Hormone therapy
  Yes 42.9 32.5 37.4 43.2 55.6
  No/unknown 57.1 67.5 62.6 56.8 44.4
HER2 statusb, %
 Positive 14.5 14.5
 Negative 80.6 80.6
 Borderline/unknown 4.9 4.9
Breast cancer subtypeb,c, %
 HR+/HER2+ 10.2 10.2
 HR+/HER2− 70.3 70.3
 HR−/HER2+ 4.3 4.3
 HR−/HER2− (Triple negative) 10.2 10.2
 Unknown 5.0 5.0
  1. SEER, Surveillance, Epidemiology, and End Results; ER, estrogen receptor; BCS, breast conserving surgery; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PR, progesterone receptor
  2. aInformation on initial surgery was available for breast cancers diagnosed from 1998+ (N = 330,766)
  3. bHER2 status was routinely collected in 2010+. Estimates include first breast cancers diagnosed from 2010 to 2015 and followed through 2016 (N = 115,835)
  4. cHR+ = ER+ and/or PR+; HR− = ER− and PR−
\